NCT06166056 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Bronchiectasis

Interventions

DRUG

CHF6333

CHF6333 Part I SAD; CHF6333 Part II MD.

DRUG

CHF6333 Placebo

Placebo Part I SAD; Placebo Part II MD.

Trial Locations (9)

NOT_YET_RECRUITING

Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge

RECRUITING

Tayside Medical Science Centre, Ninewells Hospital & Medical School, Dundee

RECRUITING

NHS Lothian, Edinburgh

RECRUITING

Glasgow Royal Infirmary, Glasgow

WITHDRAWN

The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital, Leeds

RECRUITING

Royal Bromptom Hospital (NHS Guy's and Thomas'), London

RECRUITING

Manchester University NHS Foundation Trust, Manchester

RECRUITING

Medicines Evaluation Unit (MEU), Manchester

NOT_YET_RECRUITING

University Hospital Southampton NHS Foundation Trust, Southampton

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY